Efforts to develop psychosocial interventions that specifically target social cognition in
schizophrenia spectrum disorders began nearly two decades ago. The field has matured …

Deficits in social cognition are pervasive and characteristic of neurodevelopmental disorders
(NDDs). Clinical trials of intranasal oxytocin (IN-OT) to improve social cognition have yielded …

Schizophrenia is a complex and multifactorial disorder generally diagnosed in young adults
at the time of the first psychotic episode of delusions and hallucinations. These positive …

Schizophrenia is a form of mental disorder that is behaviorally characterized by abnormal
behavior, such as social function deficits or other behaviors that are disconnected from …

Social disability is a defining characteristic of schizophrenia and a substantial public health
problem. It has several components that are difficult to disentangle. One component, social …

Social anxiety is a form of anxiety characterized by continuous fear of one or more social or
performance situations. Although multiple treatment modalities (cognitive behavioral …

Impairments in social cognition are common in schizophrenia and predict poor functional
outcome. The purpose of this proof-of-concept randomized, parallel group clinical trial was …

Intranasal insulin has shown efficacy in patients with Alzheimer's disease (AD), but there are
no preclinical studies determining whether or how it reaches the brain. Here, we showed …

Accumulating research demonstrates the potential of intranasal delivery of
psychopharmacological agents to treat a range of psychiatric disorders and symptoms. It is …

Oxytocin, a neuropeptide synthesized by the hypothalamus, plays a central role in human
social behavior, social cognition, anxiety, mood, stress modulation, and fear learning and …